Back to Journals » Patient Preference and Adherence » Volume 2

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction

Authors Konstantinos Giannitsas, Angelis Konstantinopoulos, Christos Patsialas, Petros Perimenis

Published 23 April 2008 Volume 2008:2 Pages 149—155

Konstantinos Giannitsas, Angelis Konstantinopoulos, Christos Patsialas, Petros Perimenis

Department of Urology, Medical School, University of Patras, Patras, Greece

Abstract: Sildenafil was the first orally administered phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. Its successful introduction into clinical practice was soon followed by the launch of two other phosphodiesterase-5 inhibitors: vardenafil and tadalafil. The plethora of choices made the question “which PDE-5 inhibitor?” relevant for patients and clinicians. Despite the lack of head-to-head comparative trials it is widely accepted that there are no significant differences in their safety and efficacy. Therefore a number of studies set out to determine which of the inhibitors patients would prefer and reasons for that preference. The majority of published trials show a preference for tadalafil. Others have argued that preference trials have several methodological flaws and data favoring tadalafil with its long duration of action do not reflect real-life prescription filling and sales figures. But even if one of the available PDE-5 inhibitors is chosen to treat erectile dysfunction what is the long-term compliance? A significant percentage of men initiating treatment switch between inhibitors or discontinue therapy. Reasons for that seem to often be unrelated to efficacy or tolerability and include emotional and social factors determining couples’ and individuals’ sexual and treatment seeking behavior.

Keywords: PDE-5 inhibitors, sildenafil, vardenafil, tadalafil, preference, adherence

Download Article [PDF] 

Readers of this article also read:

Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice

Melariri P, Kalombo L, Nkuna P, Dube A, Hayeshi R, Ogutu B, Gibhard L, deKock C, Smith P, Wiesner L, Swai H

International Journal of Nanomedicine 2015, 10:1493-1503

Published Date: 20 February 2015

How do COPD comorbidities affect ICU outcomes?

Ongel EA, Karakurt Z, Salturk C, Takir HB, Burunsuzoglu B, Kargin F, Ekinci GH, Mocin O, Gungor G, Adiguzel N, Yilmaz A

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1187-1196

Published Date: 17 October 2014

Central airways remodeling in COPD patients

Pini L, Pinelli V, Modina D, Bezzi M, Tiberio L, Tantucci C

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:927-933

Published Date: 1 September 2014

Multifunctional materials for bone cancer treatment

Marques C, Ferreira JMF, Andronescu E, Ficai D, Sonmez M, Ficai A

International Journal of Nanomedicine 2014, 9:2713-2725

Published Date: 28 May 2014

Pathogenesis of hyperinflation in chronic obstructive pulmonary disease

Gagnon P, Guenette JA, Langer D, Laviolette L, Mainguy V, Maltais F, Ribeiro F, Saey D

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:187-201

Published Date: 15 February 2014

P-wave indices in patients with pulmonary emphysema: do P-terminal force and interatrial block have confounding effects?

Chhabra L, Chaubey VK, Kothagundla C, Bajaj R, Kaul S, Spodick DH

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:245-250

Published Date: 14 May 2013

Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain

Nicole Rae Yurgin, Kristina Secnik Boye, Tatiana Dilla, Núria Lara Suriñach, Xavier Badia Llach

Patient Preference and Adherence 2008, 2:87-95

Published Date: 8 April 2008